Prof. Dr. Yasemin Kemal

Publications scientifiques

Les références bibliographiques sont présentées dans leur langue originale.

Articles dans des revues scientifiques

1. Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, Saura C, Schneeweiss A, Toi M, Chae YS, Kemal Y, Chaudhari M, Şendur MAN, Yamashita T, Casalnuovo M, Danso MA, Liu J, Shetty J, Herbolsheimer P, Loibl S; DESTINY-Breast09 Trial Investigators. N Engl J Med. 2026 Feb 5;394(6):551-562. doi: 10.1056/NEJMoa2508668. Epub 2025 Oct 29. PMID: 41160818
2. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K, Majem M, Şendur MAN, Czyżewicz G, Caro RB, Lee KH, Johnson ML, Karadurmuş N, Grohé C, Baka S, Csőszi T, Ahn JS, Califano R, Yang TY, Kemal Y, Ballinger M, Cuchelkar V, Graupner V, Lin YC, Chakrabarti D, Bhatt K, Cai G, Iannone R, Reck M; IMforte investigators. Lancet. 2025 Jun 14;405(10495):2129-2143. doi: 10.1016/S0140-6736(25)01011-6. Epub 2025 Jun 2. PMID: 40473449
3. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study. Sahin TK, Kemik F, Muglu H, Acikgöz Yildiz B, Biter S, Tunbekici S, Oruc A, Guren AK, Kaban K, Guzel HG, Erol C, Aykan MB, Koylu B, Ekinci OB, Deliktas Onur I, Kalem A, Altunok O, Seyyar M, Guney B, Akdogan O, Ismayilov R, Ardic FS, Yazici M, Majidova N, Turker S, Esin E, Cabuk D, Yasar HA, Oguz A, Yazici O, Gursu RU, Yılmaz M, Yesil Cinkir H, Ates O, Celik E, Karadurmus N, Demirci U, Ozturk B, Mandel NM, Bayoglu IV, Araz M, Goker E, Bayram E, Erdem D, Selcukbiricik F, Basaran G, Sezer A, Dogu GG, Kemal Y, Bilici A, Gunduz S, Guven DC, Aksoy S. Ther Adv Med Oncol. 2026 Mar 13;18:17588359261430583. doi: 10.1177/17588359261430583. eCollection 2026. PMID: 41835339
4. Major and minor salivary gland cancers: A multicenter retrospective study. Hacioglu MB, Erdogan B, Bardakcı M, Algın E, Gulbagcı B, Hacibekiroglu I, Hamdard J, Olmez OF, Akkus H, Oksuzoglu B, Goksu SS, Dae SA, Sumbul AT, Ugraklı M, Karaagac M, Sahin E, Cabuk D, Ozer O, Yavuzsen T, Arıkan R, Köstek O, Atcı MM, Sakin A, Deligonul A, Bayır D, Dincer M, Unsal O, Yazıcı O, Zeynelgil E, Gulmez A, Harputluoglu H, Erol C, Sendur MAN, Aytekin A, Akagunduz B, Oner I, Er O, Oztosun B, Gumus M, Selçukbiricik F, Aykan MB, Karadurmus N, Degerli E, Demirci NS, Turkmen E, Şakalar T, Secmeler S, Tanrıverdi O, Alkan A, Kemal Y, Cil I, Unal C, Iriagaç Y, Alan O, Balli S, Urun Y, Ozcan E, Turhal NS, Cicin I. Head Neck. 2023 Jul;45(7):1643-1653. doi: 10.1002/hed.27376. Epub 2023 Apr 21. PMID: 37084179
5. Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis. Güzel HG, Kıvrak Salim D, Kılıçkap S, Kemal Y, Akosman C, Köseoğlu Ç, Coşkun A, Orman S, Efil SC, Baş O, Zeynelgil E, Çelik H, Terzi A, Karaçelik T, Karadurmuş N, Çubukçu E, Başoğlu Tüylü T, Bilgin B, Erman M, Karakaya S, Eser K, Atağ E, Karakurt Eryılmaz M, Öztürk B. Oncologist. 2026 Mar 9;31(4):oyag092. doi: 10.1093/oncolo/oyag092. PMID: 41838398
6. Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group. Seyyar M, Şancı PC, Doğan A, Biter S, Köşeci T, Balçık OY, Karabel SS, Kalem A, Akosman C, Pilancı KN, Onur İD, Arslan ÜY, Kemal Y, Avcı T, Şahbazlar M, Akay S, Kahraman EG, Bayramgil A, Altıntaş YE, Tünbekici S, Göker E, Çolak C, Demir T, Demirağ G, Güneysu GG, Aykan MB, Nazlı İ, Alkan O, Ökten İN, Çolak R, Yılmaz M, Gür HB, Hacıbekiroğlu İ, Sönmez M, Özyurt N, Aydın O, Ertürk K, Şahin E, Karakayalı A, Baydar E, Çıtakkul İ, Emin G, Yıldırım A, Gülmez A, Özberk U, Algın E, Köseoğlu Ç, Uzundere FK, Urakçı Z, Akpunar M, Alkan A, Süner A, Peker P, Camadan YA, Can LŞ, Telli TA, Majidova N, Uzun M, Özkan MK, Baykara M, Güzel HG, Yıldırım HÇ, Kefeli U, Çabuk D, Kus T. BMC Cancer. 2026 Aug 3;26(1):1047. doi: 10.1186/s12885-026-16667-y. PMID: 42693417
7. Cutaneous metastasis of colon adenocarcinoma. Kemal Y, Odabaşı EA, Kemal Ö, Bakırtaş M. Turk J Surg. 2018 Jan 3;34(3):237-239. doi: 10.5152/turkjsurg.2017.3298. eCollection 2018. PMID: 30302429
8. PD-L1 Expression in Medullary Thyroid Carcinoma and Its Association with Clinicopathological Findings. Kemal Y, Çalişkan S, Gun S, Kefeli M. Turk Patoloji Derg. 2022;38(2):106-113. doi: 10.5146/tjpath.2021.01558. PMID: 34580845
9. Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study. Karci E, Bilici A, Bayram B, Celayir M, Ozyurt N, Uluc BO, Eken A, Basaran G, Demirci U, Kemal Y, Oruncu MB, Olmez OF, Selcukbiricik F, Korkmaz T, Erturk I, Bilgetekin I, Celik S, Turkel A, Alkan A, Sakin A, Can O, Gunaldi M, Esin E, Yildiz O. Cancers (Basel). 2024 Oct 3;16(19):3389. doi: 10.3390/cancers16193389. PMID: 39410009
10. The Frequency of Human Papilloma Virus in Laryngeal Squamous Cell Carcinoma. Kemal Y, Kemal O, Kefeli M, Gun S, Bel A, Sahin N. J Coll Physicians Surg Pak. 2019 Aug;29(8):788-789. doi: 10.29271/jcpsp.2019.08.788. PMID: 31358108
11. Epithelial membrane protein 1 expression in ovarian serous tumors. Demirag GG, Kefeli M, Kemal Y, Yucel I. Oncol Lett. 2016 Mar;11(3):2140-2144. doi: 10.3892/ol.2016.4202. Epub 2016 Feb 8. PMID: 26998138
12. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study. Yıldırım HÇ, Kutlu Y, Mutlu E, Aykan MB, Korkmaz M, Yalçın S, Şakalar T, Celayir ÖM, Kayıkçıoğlu E, Aslan F, Hafızoğlu E, Altıntaş YE, Keskinkılıç M, Chalabiyev E, Çelebi A, Dursun B, Kapar C, Özen M, Acar Ö, Dülgar Ö, Kut E, Biter S, Kus F, Almuradova E, Erdoğan AP, Saray S, Güven DC, Şimşek ET, Üskent N, Kemal Y, Çakar B, Açıkgöz Ö, Kılıçkap S, Aksoy S. Int J Clin Oncol. 2024 Mar;29(3):258-265. doi: 10.1007/s10147-023-02460-5. Epub 2024 Feb 4. PMID: 38310597
13. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG). Akyildiz A, Guven DC, Koksal B, Karaoglan BB, Kivrak D, Ismayilov R, Aslan F, Sutcuoglu O, Yazici O, Kadioglu A, Alan O, Majidova N, Erciyestepe M, Ozcan E, Akdag G, Taban H, Kaya AO, Guliyev M, Yildirim N, Sakalar T, Yazilitas D, Unal C, On S, Biter S, Demirci NS, Senler FC, Kemal Y, Halil OD, Gullu I, Aksoy S. Eur Arch Otorhinolaryngol. 2024 Sep;281(9):4991-4999. doi: 10.1007/s00405-024-08744-4. Epub 2024 May 25. PMID: 38795147
14. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Özdemir Ö, Zengel B, Yildiz Y, Uluç BO, Cabuk D, Ozden E, Salim DK, Paydas S, Demir A, Diker O, Pilanci KN, Sönmez ÖU, Vatansever S, Dogan I, Gulmez A, Cakar B, Gursoy P, Yildirim ME, Ayhan M, Karadurmus N, Aykan MB, Cevik GT, Sakalar T, Hacibekiroglu I, Gülbagci BB, Dincer M, Garbioglu DB, Kemal Y, Nayir E, Taskaynatan H, Yilmaz M, Avci O, Sari M, Coban E, Atci MM, Esen SA, Telli TA, Karatas F, Inal A, Demir H, Kalkan NO, Yilmaz C, Tasli F, Alacacioglu A. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310. Epub 2022 Jun 20. PMID: 35703239
15. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy. Delikgoz Soykut E, Kemal Y, Karacin C, Karaoglanoglu O, Kurt M, Aytac Arslan S. J Med Imaging Radiat Oncol. 2022 Feb;66(1):146-157. doi: 10.1111/1754-9485.13341. Epub 2021 Oct 10. PMID: 34632714
16. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group. Gürbüz M, Kutlu Y, Akkuş E, Köksoy EB, Köse N, Öven BB, Uluç BO, Demiray AG, Erdem D, Demir B, Turhal NS, Üskent N, Akbaş S, Selçukbiricik F, İnal A, Bilici A, Ölmez ÖF, Çabuk D, Ünal Ç, Hızal M, Şendur MAN, Korkmaz M, Karadurmuş N, Ertürk İ, Göksu SS, Tatlı AM, Güven DC, Kılıçkap S, Paksoy N, Aydıner A, Çınkır HY, Özkul Ö, Öztürk A, Ballı S, Kemal Y, Erdoğan AP, Er Ö, Yumuk PF, Demirkazık A. J Cancer Res Clin Oncol. 2022 Dec;148(12):3547-3555. doi: 10.1007/s00432-022-04087-x. Epub 2022 Jun 11. PMID: 35689097
17. The value of red blood cell distribution width in endometrial cancer. Kemal Y, Demirag G, Baş B, Önem S, Teker F, Yücel İ. Clin Chem Lab Med. 2015 Apr;53(5):823-7. doi: 10.1515/cclm-2014-0699. PMID: 25860865
18. Real-world associations of pathological complete response and survival with neoadjuvant pembrolizumab in early TNBC: a Turkish Oncology Group study. Muğlu H, Sünger E, Özkan O, Şahin TK, Köylü B, Helvacı K, Kemal Y, Demirci U, Selçukbiricik F, Başaran G, Uluç BO, Ölmez ÖF, Aksoy S, Gökmen E, Bilici A. Sci Rep. 2026 Apr 3;16(1):23393. doi: 10.1038/s41598-026-47351-7. PMID: 41933152
19. Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group. Fidan MC, Keskin Uzundere F, Biter S, Durnalı A, Kalacı E, Odabaşı Bükün H, Kocaaslan E, Eniseler EB, Durukan BM, Tünbekici S, Özen Engin E, Bakır Kahveci G, Emin G, Şahin E, Kölemen E, Gökmen A, Aslan F, Şakalar T, Kemal Y, Urakçı Z, Kara İO, Kılıçkap S, Şahin AB, Işık S, Erdoğan AP, Akın S, Göker E, Hacıbekiroğlu İ, Küçükarda A, Demirci NS, Alan Ö. JCO Glob Oncol. 2026 Sep;12(9):e2600317. doi: 10.1200/GO-26-00317. Epub 2026 Sep 9. PMID: 42715501
20. Clinicopathological characteristics of thyroid cancer in patients on dialysis for end-stage renal disease. Demirer AN, Kemal Y, Gursoy A, Sahin M, Tutuncu NB. Thyroid. 2008 Jan;18(1):45-50. doi: 10.1089/thy.2006.0310. PMID: 18302517
21. Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with glioblastoma. Yersal Ö, Odabaşi E, Özdemir Ö, Kemal Y. Mol Clin Oncol. 2018 Oct;9(4):453-458. doi: 10.3892/mco.2018.1695. Epub 2018 Aug 9. PMID: 30233797
22. Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis. Kemal Y, Yucel I, Ekiz K, Demirag G, Yilmaz B, Teker F, Ozdemir M. Asian Pac J Cancer Prev. 2014;15(6):2651-4. doi: 10.7314/apjcp.2014.15.6.2651. PMID: 24761879
23. A case of gastric cancer with liver metastases had a complete response with cisplatin and capecitabine as third-line chemotherapy. Teker F, Canbaz F, Kemal Y, Yucel I. J Cancer Res Ther. 2015 Oct-Dec;11(4):1026. doi: 10.4103/0973-1482.150348. PMID: 26881594
24. Quality of life in colorectal cancer patients during chemotherapy in the era of monoclonal antibody therapies. Teker F, Demirag G, Erdem D, Kemal Y, Yucel I. J BUON. 2015 Mar-Apr;20(2):443-51. PMID: 26011334
25. A patient-based study on the adherence of physicians to guidelines for the management of type 2 diabetes in Turkey. Satman I, Imamoglu S, Yilmaz C; ADMIRE Study Group. Diabetes Res Clin Pract. 2012 Oct;98(1):75-82. doi: 10.1016/j.diabres.2012.05.003. Epub 2012 May 29. PMID: 22652276
26. Antithyroid peroxidase antibody positivity is associated with lower incidence of metastasis in breast cancer. Kemal Y, Demirag G, Ekiz K, Yucel I. Mol Clin Oncol. 2015 May;3(3):629-632. doi: 10.3892/mco.2015.521. Epub 2015 Mar 2. PMID: 26137279
27. Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey. Teker F, Yilmaz B, Kemal Y, Kut E, Yucel I. Asian Pac J Cancer Prev. 2014;15(16):6727-32. doi: 10.7314/apjcp.2014.15.16.6727. PMID: 25169516
28. Düzgün B, Kemal Ö, Kemal Y, Gün S, Demirel E. PD-L1 positivity and relation with clinicopathological characteristics in head and neck squamous cell carcinoma patients. Deneysel ve Klinik Tıp Dergisi. 2025.

Sources: PubMed · DergiPark